Targeted Genetics Expands AAV Vector Patent Portfolio
Targeted Genetics Expands AAV Vector Patent Portfolio

Targeted Genetics Corporation (Nasdaq: TGEN - News) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector technology. U.S. patent #6,893,865, titled "Methods, Compositions and Cells for Encapsidating Recombinant Vectors in AAV Particles," expands Targeted Genetics' AAV vector systems used for gene delivery. Targeted Genetics' leading gene delivery vehicle, AAV, is used to deliver a gene of interest into cells of the patient to impact disease. The Company uses AAV technology for its current development programs targeting AIDS prophylaxis, inflammatory arthritis, hyperlipidemia, congestive heart failure, and Huntington's disease. AAV can be used in general to deliver a broad range of nucleic acids as disease therapeutics or prophylactics.
ADVERTISEMENT


The patent describes AAV vectors that utilize a small, human DNA sequence, P1. AAV vectors require a recognition signal in order to promote the formation of AAV viral particles containing the therapeutic gene of interest. In this patented vector system, the human P1 segment efficiently provides that function.

"Targeted Genetics' latest patent expands the Company's AAV vector technology," said Barrie J. Carter, Ph.D., chief scientific officer of Targeted Genetics. "This patent complements our existing patent that issued for the use of P1 in our manufacturing processes. The utilization of P1 provides alternative AAV design strategies that enhance and protect our competitive position. This expansion of Targeted Genetics' patent portfolio further solidifies our leadership position in the field of AAV vector technology and AAV manufacturing."

About Targeted Genetics

Targeted Genetics Corporation develops molecular medicines for the prevention and treatment of acquired and inherited diseases. The Company has clinical product development programs targeting AIDS prophylaxis and inflammatory arthritis. The Company also has a promising pipeline of preclinical product development programs focused on hyperlipidemia, congestive heart failure, and Huntington's disease. For more information about Targeted Genetics, visit its website at www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our intellectual property, research programs and clinical trials, our product development and our potential development platforms including AAV vectors and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's pipeline and potential application of this patent to any future product candidates are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, results of animal research are not necessarily indicative of results in humans, the timing, nature and results of our research, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the period ended March 31, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

Contact: Stacie D. Byars, Director, Communications of Targeted Genetics Corporation, +1-206-521-7392.




--------------------------------------------------------------------------------
Source: Targeted Genetics Corporation


Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech News

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech